Navitoclax: all 38 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLNot yet recruitingNCT05054465Phase 1/2
• Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisCompletedNCT04472598Phase 3Results posted
• Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsTerminatedNCT03366103Phase 1/2Results posted
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT02079740Phase 1/2Results posted
• A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00481091Phase 1/2Results posted
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingNCT05864742Phase 2
• HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesWithdrawnNCT05740449Phase 1/2
• Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeCompletedNCT05564650Phase 1
• Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingNCT05455294Phase 1
• Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1
• Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxActive, not recruitingNCT05222984Phase 1
• Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisTerminatedNCT04480086Phase 1
• Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
• Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingNCT04454658Phase 1
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingNCT04041050Phase 1
• A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedNCT03181126Phase 1
• A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian CancerCompletedNCT02591095Phase 2
• Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingNCT01989585Phase 1/2
• Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedNCT01557777Phase 2
• A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)WithdrawnNCT01423539Phase 2
• A Study to Assess the Effect of Rifampin on the Metabolism of NavitoclaxCompletedNCT01121133Phase 1
• A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)CompletedNCT01087151Phase 2
• Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female SubjectsCompletedNCT01053520Phase 1
• A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).CompletedNCT01021358Phase 1
• A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer SubjectsCompletedNCT01009073Phase 1
• Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With CancerCompletedNCT00982566Phase 1
• Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing RegimenWithdrawnNCT00918450Phase 2
• Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid TumorsCompletedNCT00891605Phase 1
• Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With CancerCompletedNCT00888108Phase 1
• Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid TumorsCompletedNCT00887757Phase 1
• A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With CancerCompletedNCT00878449Phase 1
• Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedNCT00788684Phase 1
• Assess the Oral Bioavailability of New ABT-263 FormulationsCompletedNCT00743028Phase 1
• A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological MalignanciesCompletedNCT00445198Phase 1/2
• A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2

← Navitoclax overview